All In Biotech

Drug Trial Radar · NCT07667569

A Study to Learn How Safe ACT-777991 is and How Well it Works in Adults With Non-segmental Vitiligo

A Phase 2a, Proof of Concept, Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial to Assess the Efficacy and Safety of ACT-777991 in Adults With Non-segmental Vitiligo

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Oct 6, 2026

Primary completion

Jun 28, 2027

Study completion Jul 31, 2027

Sponsor

Lead sponsor
Idorsia Pharmaceuticals Ltd.Industry
Sponsor type
Industry
First posted
Jun 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to learn how well ACT-777991 works, how safe it is and how well it is tolerated by adults with non-segmental vitiligo. The main question this clinical trial aims to answer is: • Can ACT-777991 help return color to the skin of the face of adults with non-segmental vitiligo? Researchers will compare ACT-777991 to placebo (a look-alike inactive treatment that contains no medicine) to see if ACT-777991 works to treat non-segmental vitiligo. Trial participants will: * Take the trial intervention (either ACT-777991 or placebo) daily for 24 weeks. * Visit the clinic 7 times for check-up and tests.

Conditions

  • Non-Segmental Vitiligo

Interventions

  • ACT-777991Drug

    ACT-777991 tablets

  • PlaceboDrug

    ACT-777991-matching placebo tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Main primary outcome measure: Percentage change from baseline in Facial Vitiligo Area Scoring Index (F-VASI) based on Blinded Independent Central Reading (BICR) at Week 24Time frame: Baseline; Week 24
  2. Supplementary primary outcome measure: Percentage change from baseline in F-VASI based on investigator assessment at Week 24Time frame: Baseline; Week 24
  3. Supplementary primary outcome measure: Percentage change from baseline in F-VASI at Week 4, 8 and 16Time frame: Baseline; Week 4, Week 8; Week 16
  4. Supplementary primary outcome measure: Achievement of F-VASI50 at Week 4, 8, 16 and 24Time frame: Baseline; Week 4; Week 8; Week 16; Week 24
  5. Supplementary primary outcome measure: Achievement of F-VASI75 at Week 4, 8, 16 and 24Time frame: Baseline; Week 4; Week 8; Week 16; Week 24
  6. Supplementary primary outcome measure: Achievement of F-VASI90 at Week 4, 8, 16 and 24Time frame: Baseline; Week 4; Week 8; Week 16; Week 24

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • Vitiligo & Pigmentation Institute of Southern California

    Los Angeles, California · Recruiting

  • Centrum Medyczne Angelius Provita

    Katowice, Poland · Not yet recruiting

  • Medistica s.c.

    Krakow, Poland · Not yet recruiting

  • Małopolskie Centrum Kliniczne

    Krakow, Poland · Not yet recruiting

  • DermoDent Centrum Medyczne Aldona Czajkowska Rafał Czajkowski s.c.

    Osielsko, Poland · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.